Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.

Intravacc is partnering with Wageningen Bioveterinary Research and Utrecht University to develop an intranasal COVID-19 vaccine.

The FDA approved Eli Lilly’s Baqsimi (glucagon) nasal powder 3 mg to treat severe hypoglycemia in diabetics 4 years of age and older.

Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.